Related Experiment Videos

[The use of sirdalud in cerebral palsy in children]

Insights

Low doses of Sirdalud effectively treated cerebral palsy in children, improving motor, autonomic, and emotional functions without side effects. This study highlights Sirdalud

Area of Science:

  • Neurology
  • Pediatrics
  • Pharmacology

Background:

  • Cerebral palsy (CP) is a group of movement disorders present from birth or early childhood.
  • Diplegic CP, a severe form, significantly impacts motor function.
  • Effective and safe therapeutic options for managing CP symptoms are crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of Sirdalud monotherapy in children with severe diplegic cerebral palsy.
  • To assess the impact of Sirdalud on motor, autonomic, and mental spheres in pediatric CP patients.
  • To investigate the effects of Sirdalud on neurophysiological parameters in children with CP.

Main Methods:

  • A cohort of 30 diplegic children with severe cerebral palsy participated.
  • Sirdalud was administered as monotherapy for 2-6 weeks at low doses (1mg or 2mg thrice daily).
  • Electroneuromyographic analysis was performed to assess neurophysiological changes.

Main Results:

  • Positive effects were observed across motor, autonomic, and mental (emotional) functions.
  • Sirdalud demonstrated high efficacy in patients post-orthopedic-surgical treatment.
  • Electroneuromyographic analysis revealed decreased synergistic tonic activity and improved supraspinal influences and segmental interaction.

Conclusions:

  • Low-dose Sirdalud monotherapy is effective in managing severe cerebral palsy in children.
  • Sirdalud treatment resulted in significant improvements in various functional spheres without reported side effects.
  • The findings support Sirdalud as a safe and beneficial therapeutic agent for pediatric cerebral palsy.

Related Concept Videos